Journal of the European Academy of Dermatology and Venereology最新文献

筛选
英文 中文
Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules. Q开关紫翠宝石激光联合外用雷帕霉素治疗22例激光耐受性面部咖啡色黄斑患者。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-20 DOI: 10.1111/jdv.20413
Xumei Wu, Chaoyang Miao, Yuanxiang Liu, Xinrong Zhao, Yimeng Zhang, Zigang Xu
{"title":"Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules.","authors":"Xumei Wu, Chaoyang Miao, Yuanxiang Liu, Xinrong Zhao, Yimeng Zhang, Zigang Xu","doi":"10.1111/jdv.20413","DOIUrl":"https://doi.org/10.1111/jdv.20413","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption. 探索CARD14相关丘疹鳞状溃疡的共同临床特征和成功的治疗干预。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-20 DOI: 10.1111/jdv.20420
S Vanya J Rossel, Adam Reich, Avital Baniel, Katarzyna Wertheim-Tysarowska, Leonie H Frommherz, Daniel Nolberczak, Aleksandra Lesiak, Bartlomiej Kwiek, Katarzyna Osipowicz, Marcel W Bekkenk, Liesbeth Spruijt, Marieke M B Seyger, Marta Kołt-Kamińska, Kathrin Giehl, Joanna Nartbutt, Maaike Vreeburg, Peter M Steijlen, Eli Sprecher, Michel van Geel, Antoni H Gostyński
{"title":"Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption.","authors":"S Vanya J Rossel, Adam Reich, Avital Baniel, Katarzyna Wertheim-Tysarowska, Leonie H Frommherz, Daniel Nolberczak, Aleksandra Lesiak, Bartlomiej Kwiek, Katarzyna Osipowicz, Marcel W Bekkenk, Liesbeth Spruijt, Marieke M B Seyger, Marta Kołt-Kamińska, Kathrin Giehl, Joanna Nartbutt, Maaike Vreeburg, Peter M Steijlen, Eli Sprecher, Michel van Geel, Antoni H Gostyński","doi":"10.1111/jdv.20420","DOIUrl":"https://doi.org/10.1111/jdv.20420","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis. 免疫检查点抑制剂诱发黑色素瘤患者胰酶升高:发病率、管理和治疗--多中心分析。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-20 DOI: 10.1111/jdv.20384
M Brandlmaier, M Hoellwerth, T Silly, C Hoeller, L Koch, E Richtig, K Binder, B Lange-Asschenfeldt, M Barta, M Schmid-Simbeck, F Froehlich, R Dummer, L Muigg, W Hitzl, P Koelblinger
{"title":"Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.","authors":"M Brandlmaier, M Hoellwerth, T Silly, C Hoeller, L Koch, E Richtig, K Binder, B Lange-Asschenfeldt, M Barta, M Schmid-Simbeck, F Froehlich, R Dummer, L Muigg, W Hitzl, P Koelblinger","doi":"10.1111/jdv.20384","DOIUrl":"https://doi.org/10.1111/jdv.20384","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICI) are considered standard-of-care in the systemic treatment of melanoma. However, management of certain ICI-associated adverse events (AE) can be challenging. Incidence, course and management of immune checkpoint inhibitor-induced pancreatic injury (ICIPI) are not well-documented and specific diagnostic and therapeutic algorithms are lacking. Current management includes serological monitoring of pancreatic enzymes, radiographic imaging and corticosteroid or further immunosuppressive treatment.</p><p><strong>Objectives: </strong>Based on previous data regarding adjuvant ICI treatment, we suspected that elevation of pancreatic enzymes may occur more frequently than reported while the clinical relevance of-particularly asymptomatic-ICIPI is still unclear.</p><p><strong>Methods: </strong>A collaboration of eight Austrian and Swiss dermato-oncology centres was established to retrospectively analyse a large cohort of ICI-treated patients regarding incidence and management of ICIPI. Additionally, a questionnaire-based survey concerning ICIPI-management was conducted.</p><p><strong>Results: </strong>Among 1516 melanoma patients receiving ICI therapy, 204 patients exhibited ≥CTCAE II° lipase elevation. Of these patients, 41 (20.1%) had symptoms suggestive of pancreatitis. Immunotherapy was interrupted or discontinued due to pancreatic AE in almost half of the patients. Systemic corticosteroids were administered in 103 patients (50.5%), with higher doses reported in symptomatic cases. Six per cent of asymptomatic patients had radiographically proven pancreatitis. Maximum lipase elevation was >5xULN in all of these patients.</p><p><strong>Conclusion: </strong>Routine lipase monitoring was conducted in all participating centres, although not recommended in respective guidelines. Elevation of serum lipase was observed more frequently than recently reported. Although radiographic findings indicating pancreatitis were rare in asymptomatic patients, ICI treatment was frequently paused or discontinued and systemic steroids were administered. To reduce the existing uncertainty in routine clinical practice reflected by our findings, we provide an algorithm to guide the monitoring and management of potential pancreatic adverse events. Lipase measurement should be limited to symptomatic patients and/or those with radiographic findings indicative of pancreatic injury.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to 'Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa' by Holgersen et al. Holgersen 等人对 "口服罗氟司特治疗化脓性扁桃体炎的有效性、安全性和药物存活率 "的答复
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-20 DOI: 10.1111/jdv.20442
Fabrizio Martora, Teresa Battista, Luca Potestio, Matteo Megna
{"title":"Reply to 'Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa' by Holgersen et al.","authors":"Fabrizio Martora, Teresa Battista, Luca Potestio, Matteo Megna","doi":"10.1111/jdv.20442","DOIUrl":"https://doi.org/10.1111/jdv.20442","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of doxycycline for prophylaxis of sexually transmitted infections. 多西环素预防性传播感染的综述。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-18 DOI: 10.1111/jdv.20387
Scott Stratman, John G Zampella
{"title":"Review of doxycycline for prophylaxis of sexually transmitted infections.","authors":"Scott Stratman, John G Zampella","doi":"10.1111/jdv.20387","DOIUrl":"10.1111/jdv.20387","url":null,"abstract":"<p><p>The surging rates of STIs necessitate medical practitioners in the appropriate specialties to focus on rapid recognition, treatment and prevention of these conditions. Through both pre- and post-exposure prophylaxis with doxycycline, dermatologists can provide up-to-date treatment in the field of venereology. Herein, we review the results of clinical trials in the available literature that investigate doxycycline prophylaxis in the prevention of bacterial STIs. A search was performed using the PubMED and Scopus databases which yielded six clinical trials for our review. Based on the results of these clinical trials, doxycycline prophylaxis offers significant reductions in bacterial STIs, specifically in men who have sex with men (MSM). Additional research is needed in other high-risk groups, including females. Moreover, additional research is needed to determine the effects of doxycycline prophylaxis on tetracycline resistance in STI-causing bacteria. As the utilization of doxycycline prophylaxis for STIs becomes more common, it is important that dermatologists become familiar with the data surrounding this prevention regimen and patient populations who may seek to know more about it. More research is needed to determine benefits in other subpopulations, antimicrobial resistance and cost effectiveness.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Terra firma-forme dermatosis" on the proximal nail fold. 指甲近端褶皱上的 "Terra firma-forme 皮肤病"。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-16 DOI: 10.1111/jdv.20431
Marisa Mathieu, Florence Dehavay, Bertrand Richert
{"title":"\"Terra firma-forme dermatosis\" on the proximal nail fold.","authors":"Marisa Mathieu, Florence Dehavay, Bertrand Richert","doi":"10.1111/jdv.20431","DOIUrl":"https://doi.org/10.1111/jdv.20431","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflectance confocal microscopy for margin mapping of melanoma of the lentigo maligna type: A systematic review and meta-analysis. 反射共聚焦显微镜用于绘制恶性白斑型黑色素瘤的边缘图:系统回顾和荟萃分析。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-15 DOI: 10.1111/jdv.20383
Yasmin Mesquita, Isabela R Marques, Izabela Pera Calvi, Sara A Cruz, Amanda Godoi, Izadora L Lapenda, Rafaela de Moraes-Souza, Jessica H Relvas, Maysa Vilbert, Kishwer S Nehal, Cristian Navarrete-Dechent
{"title":"Reflectance confocal microscopy for margin mapping of melanoma of the lentigo maligna type: A systematic review and meta-analysis.","authors":"Yasmin Mesquita, Isabela R Marques, Izabela Pera Calvi, Sara A Cruz, Amanda Godoi, Izadora L Lapenda, Rafaela de Moraes-Souza, Jessica H Relvas, Maysa Vilbert, Kishwer S Nehal, Cristian Navarrete-Dechent","doi":"10.1111/jdv.20383","DOIUrl":"https://doi.org/10.1111/jdv.20383","url":null,"abstract":"<p><p>Melanoma of the lentigo maligna (LM) type and its invasive counterpart, lentigo maligna melanoma (LMM), occur in chronically sun-damaged skin and tend to have subclinical extension that makes presurgical margin mapping challenging. Reflectance confocal microscopy (RCM) is a non-invasive imaging modality that enables in vivo visualization of the skin at the cellular level, allowing for adequate estimation of LM/LMM margins. We aimed to perform a systematic review and meta-analysis evaluating RCM's performance compared with histopathology in margin mapping of LM/LMM. We searched MEDLINE, Embase, Cochrane, and Clinicaltrials.gov for studies published until July 2023, assessing RCM diagnostic accuracy for presurgical LM/LMM margin delineation. Negative predictive value (NPV; number of true negatives confirmed by histopathology out of all negatives found on RCM) was our primary outcome. Secondary outcomes were proportion of agreement between RCM and histopathology, mean number of stages to clear lesion, sensitivity, and specificity. Of the 955 search results, nine studies (329 participants) were included. Pooled NPV for RCM detection of LM/LMM clear margins was 89.15% (95% CI 80.95-95.46; I<sup>2</sup> = 80%). The RCM and histopathology agreement rate was 92.09% (95% CI 84.71-96.07; I<sup>2</sup> = 57%). Mean number of stages needed to clear the lesion using RCM was 1.16 (95% CI 1.08-1.23; I<sup>2</sup> = 0). Compared with histopathology, RCM sensitivity and specificity were 91.4% (95% CI 82.2-96.1; I<sup>2</sup> = 0%) and 95.7% (95% CI 90.7-98; I<sup>2</sup> = 68%), respectively. These results support that RCM has a high concordance rate with the gold standard histopathology for presurgical LM/LMM margin mapping, constituting a valuable tool for its management.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2). 托佐拉单抗治疗中重度特应性皮炎的疗效和安全性:2a期随机对照试验(FRONTIER-2)。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-13 DOI: 10.1111/jdv.20388
J I Silverberg, M N Mustapa, F Reid, A Lei, R Smith, R Moate, A Kelly, R Chen, M Gavala, E Jimenez, M G Belvisi, M W Sadiq, C Kell, H C Pandya
{"title":"Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2).","authors":"J I Silverberg, M N Mustapa, F Reid, A Lei, R Smith, R Moate, A Kelly, R Chen, M Gavala, E Jimenez, M G Belvisi, M W Sadiq, C Kell, H C Pandya","doi":"10.1111/jdv.20388","DOIUrl":"https://doi.org/10.1111/jdv.20388","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense pruritus and eczematous lesions. Tozorakimab is a high-affinity human monoclonal antibody that neutralizes interleukin-33, a broad-acting alarmin cytokine that is over-expressed in keratinocytes of patients with AD.</p><p><strong>Objectives: </strong>This Phase 2a study (FRONTIER-2; NCT04212169) evaluated the safety and efficacy of tozorakimab in adults with moderate-to-severe AD.</p><p><strong>Methods: </strong>FRONTIER-2 was a randomized, placebo-controlled, parallel-group, double-blind study conducted from 9 December 2019 to 20 September 2022 at 32 centres across six countries. Patients were randomized 3:1:1:3 to receive placebo, tozorakimab 60 mg, tozorakimab 300 mg or tozorakimab 600 mg by subcutaneous injection once every 4 weeks for four doses. The primary endpoint was percentage change from baseline to Week 16 in the Eczema Area and Severity Index (EASI) score in patients treated with tozorakimab versus placebo. Secondary outcomes included EASI-75 responders (patients achieving ≥75% reduction from baseline in EASI score), Investigator's Global Assessment (IGA) responders (patients achieving an IGA score of 0 or 1), pharmacokinetics, immunogenicity and safety.</p><p><strong>Results: </strong>Overall, 148 patients were randomized. There was no statistically significant difference in the primary endpoint (60 mg difference of 1.3 [90% confidence interval (CI): -13.7, 16.2], p = 0.888; 300 mg: difference of 5.9 [90% CI: -10.4, 22.1], p = 0.549; 600 mg: difference of - 1.7 [90% CI: -13.4, 10.0], p = 0.807). The proportion of EASI-75 and IGA 0/1 responders at Week 16 was numerically higher in the tozorakimab 600 mg group than in the placebo group (EASI-75: 18.2% vs. 7.1%, p = 0.094; IGA 0/1: 9.1% vs. 1.8%, p = 0.113). Serum pharmacokinetics were dose-dependent, immunogenicity incidence was low and tozorakimab was well tolerated.</p><p><strong>Conclusions: </strong>FRONTIER-2 did not show a statistically significant difference in the primary endpoint for tozorakimab compared with placebo. However, numerical increases in responder rates were observed.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis. 体内反射共聚焦显微镜在早期至晚期恶性黑色素瘤光谱中的作用:系统回顾和汇总分析。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-13 DOI: 10.1111/jdv.20389
Bruna Melhoranse Gouveia, Peter M Ferguson, Serigne N Lo, Helena Collgros, Linda K Martin, Christoph Sinz, Amelia K Smit, Bruna Gallo, Genevieve Ho, Amanda Glanz, Richard A Scolyer, Anne E Cust, Pascale Guitera
{"title":"In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.","authors":"Bruna Melhoranse Gouveia, Peter M Ferguson, Serigne N Lo, Helena Collgros, Linda K Martin, Christoph Sinz, Amelia K Smit, Bruna Gallo, Genevieve Ho, Amanda Glanz, Richard A Scolyer, Anne E Cust, Pascale Guitera","doi":"10.1111/jdv.20389","DOIUrl":"https://doi.org/10.1111/jdv.20389","url":null,"abstract":"<p><p>Lentigo maligna (LM) is a growing problem worldwide and the main type of melanoma in situ in some Caucasian populations. It presents as a spectrum from atypical intraepidermal melanocytic proliferation (AIMP) to invasive lentigo maligna melanoma (LMM). Accurate diagnosis and staging are crucial for determining appropriate management strategies. To assess the role of in vivo reflectance confocal microscopy (RCM) in differentiating early and advanced stages of lentigo maligna. A systematic search was conducted on Medline, PubMed, Scopus, Web of Science, Proquest Central, Embase, Cochrane and Google Scholar. References of included and excluded studies were reviewed for additional sources. Studies involving RCM for AIMP, LM and LMM diagnosis published until 1 December 2023, were selected for analysis. Publications on other non-invasive imaging techniques, other skin diseases or those addressing only RCM surgical margins and therapeutic response without reporting RCM features were excluded. Each article was reviewed by two experts, with disagreements resolved by a third expert. Data for each RCM feature were pooled, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Features were stratified for architecture, cellular morphology and distribution. Twenty-seven articles involving 303 lesions were included. Features favouring LM over AIMP included (1) Architecture: the presence of non-edged papillae (OR 4.50, 95% CI 1.92-10.52) and (2) Cellular distribution: widespread pagetoid cells and junctional atypical cells (OR 25.06, 95% CI 4.19-148.45) and junctional nests (OR 18.06, 95% CI 3.04-106.32). Features favouring LMM over LM included (1) Architecture: epidermal disarray (OR 5.03, 95% CI 1.90-13.22), junctional disarray (OR 4.19, 95% CI 1.54-11.33) and destroyed collagen fibres (OR 3.91, 95% CI 1.80-8.44) and (2) cellular distribution: widespread pagetoid and junctional atypical cells (OR 2.71, 95% CI 1.27-5.75) and junctional nests (OR 4.48, 95% CI 2.12-9.43). This study identifies the RCM features associated with the LM/LMM spectrum.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics of iatrogenic versus idiopathic linear IgA bullous dermatosis: A systematic review. 先天性与特发性线性 IgA 大疱性皮肤病的临床特征:系统综述。
IF 8.4 2区 医学
Journal of the European Academy of Dermatology and Venereology Pub Date : 2024-11-13 DOI: 10.1111/jdv.20429
Daniel Antohi, Yasmine Oprea, Caroline Delbourgo Patton, Benedict Wu
{"title":"Clinical characteristics of iatrogenic versus idiopathic linear IgA bullous dermatosis: A systematic review.","authors":"Daniel Antohi, Yasmine Oprea, Caroline Delbourgo Patton, Benedict Wu","doi":"10.1111/jdv.20429","DOIUrl":"https://doi.org/10.1111/jdv.20429","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信